Cargando…

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

BACKGROUND: COVID-19 is a viral prothrombotic respiratory infection. Heparins exert antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed to investigate whether thromboprophylaxis with enoxaparin would prevent untoward hospitalisation and death in symptomatic, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barco, Stefano, Voci, Davide, Held, Ulrike, Sebastian, Tim, Bingisser, Roland, Colucci, Giuseppe, Duerschmied, Daniel, Frenk, André, Gerber, Bernhard, Götschi, Andrea, Konstantinides, Stavros V, Mach, François, Robert-Ebadi, Helia, Rosemann, Thomas, Simon, Noemi R, Spechbach, Hervé, Spirk, David, Stortecky, Stefan, Vaisnora, Lukas, Righini, Marc, Kucher, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243568/ https://www.ncbi.nlm.nih.gov/pubmed/35779558 http://dx.doi.org/10.1016/S2352-3026(22)00175-2

Ejemplares similares

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial
por: Voci, Davide, et al.
Publicado: (2023)

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial
por: Barco, Stefano, et al.
Publicado: (2020)

Ovid Discovery
por: Lilly, Jason A., et al.
Publicado: (2020)

Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment
por: Karaoui, Lamis R., et al.
Publicado: (2018)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Bibliotherapy: Reading OVID During COVID
por: Stip, Emmanuel, et al.
Publicado: (2020)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial
por: Alalaf, Shahla K, et al.
Publicado: (2015)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Modelling and predicting the spatio-temporal spread of cOVID-19 in Italy
por: Giuliani, Diego, et al.
Publicado: (2020)

Anticoagulation in the Elderly
por: Robert-Ebadi, Helia, et al.
Publicado: (2010)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis
por: Mumoli, Nicola, et al.
Publicado: (2021)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial
por: Alavi-Darazam, Ilad, et al.
Publicado: (2022)

Development and evaluation of a search filter to identify prognostic factor studies in Ovid MEDLINE
por: Stallings, Elena, et al.
Publicado: (2022)

A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
por: Robinson, Sian, et al.
Publicado: (2013)

Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial
por: Maradei-Pereira, João Alberto Ramos, et al.
Publicado: (2022)

Use of anticoagulants in elderly patients: practical recommendations
por: Robert-Ebadi, Helia, et al.
Publicado: (2009)

Diagnostic Management of Pregnant Women With Suspected Pulmonary Embolism
por: Robert-Ebadi, Helia, et al.
Publicado: (2022)

Glomerular disease search filters for Pubmed, Ovid Medline, and Embase: a development and validation study
por: Hildebrand, Ainslie M, et al.
Publicado: (2012)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
por: Rosencher, Nadia, et al.
Publicado: (2012)

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study
por: Albani, Filippo, et al.
Publicado: (2020)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Underuse of medical thromboprophylaxis in mobile elderly inpatients: The SWITCO65+ cohort
por: Blondon, Marc, et al.
Publicado: (2020)

Locating sex-specific evidence on clinical questions in MEDLINE: a search filter for use on OvidSP™
por: Moerman, Clara J, et al.
Publicado: (2009)

A failed attempt at developing a search filter for systematic review methodology articles in Ovid Embase
por: Neilson, Christine, et al.
Publicado: (2019)

The NICE OECD countries' geographic search filters: Part 2—validation of the MEDLINE and Embase (Ovid) filters
por: Ayiku, Lynda, et al.
Publicado: (2021)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
por: Gómez-Outes, Antonio, et al.
Publicado: (2012)

Fixed-Dose Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism Associated with COVID-19
por: Voci, Davide, et al.
Publicado: (2022)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Diagnosis of Pulmonary Embolism during Pregnancy
por: Robert-Ebadi, Helia, et al.
Publicado: (2022)

A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting
por: Zindel, Sonja, et al.
Publicado: (2012)

Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis
por: Pleming, William, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rn8md2ott04a3a9rt8t7nj2uag